https://www.onclive.com/view/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-for-psma-mhspc2026-07-31T20:33:56.567Z2026-07-31T20:33:56.567Z https://www.onclive.com/view/dr-malla-on-the-impact-of-specific-biomarkers-in-first-line-treatment-selection-for-gi-cancers2026-07-31T19:25:43.832Z2026-07-31T19:25:43.832Z https://www.onclive.com/view/how-is-optune-pax-reshaping-locally-advanced-pancreatic-cancer-care-2026-07-31T18:43:04.751Z2026-07-31T18:43:04.751Z https://www.onclive.com/view/dr-hurvitz-on-evorpacept-plus-zanidatamab-in-pretreated-her2-metastatic-breast-cancer2026-07-31T18:30:00Z2026-07-31T18:30:00Z https://www.onclive.com/view/fda-approval-insights-subcutaneous-isatuximab-via-an-on-body-delivery-system-represents-a-game-changer-in-multiple-myeloma-with-douglas-w-sborov-md-ms2026-07-31T17:39:23.260Z2026-07-31T17:39:23.260Z https://www.onclive.com/view/positioning-pd-l1-vegf-bispecifics-in-first-line-non-small-cell-lung-cancer-with-solange-peters-md-phd2026-07-31T17:30:00Z2026-07-31T17:30:00Z https://www.onclive.com/view/shorter-venetoclax-plus-azacitidine-schedule-falls-short-in-aml2026-07-31T16:12:00Z2026-07-31T16:12:00Z https://www.onclive.com/view/clinical-impact-of-chemotherapy-induced-myelosuppression-in-extensive-stage-small-cell-lung-cancer2026-07-31T16:08:37.691Z2026-07-31T16:08:37.691Z https://www.onclive.com/view/experimental-immunotherapy-may-help-patients-with-high-risk-bladder-cancer-avoid-bladder-removal-surgery2026-07-31T16:00:00Z2026-07-31T16:00:00Z https://www.onclive.com/view/understanding-the-burden-of-chemotherapy-induced-myelosuppression-in-extensive-stage-small-cell-lung-cancer2026-07-31T15:59:24.600Z2026-07-31T15:59:24.600Z https://www.onclive.com/view/precision-oncology-bispecific-antibodies-and-next-generation-targeted-therapies-are-reshaping-nsclc-care-with-chandler-park-md-stephen-v-liu-md2026-07-31T14:51:38.753Z2026-07-31T14:51:38.753Z https://www.onclive.com/view/fda-snda-submission-is-planned-for-selinexor-plus-ruxolitinib-in-myelofibrosis2026-07-31T14:03:07.363Z2026-07-31T14:03:07.363Z https://www.onclive.com/view/selinexor-maintenance-misses-pfs-end-point-in-tp53-wild-type-endometrial-cancer2026-07-31T13:55:05.505Z2026-07-31T13:55:05.505Z https://www.onclive.com/view/sarcoma-experts-answer-faqs-about-the-diagnosis-and-multidisciplinary-management-of-sarcoma2026-07-31T13:00:00Z2026-07-31T13:00:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-early-referral-for-car-t-cell-therapy2026-07-31T12:05:00Z2026-07-31T12:05:00Z https://www.onclive.com/view/when-to-act-red-flags-for-ca-lems-in-small-cell-lung-cancer-and-the-nccn-testing-threshold2026-07-31T12:05:00Z2026-07-31T12:05:00Z https://www.onclive.com/view/how-checkpoint-inhibition-is-used-in-locally-advanced-disease2026-07-31T12:05:00.000Z2026-07-31T12:05:00Z https://www.onclive.com/view/relapsed-refractory-multiple-myeloma-evolving-treatment-landscape-and-sequencing2026-07-31T12:00:00Z2026-07-31T12:00:00Z https://www.onclive.com/view/defining-locally-advanced-cutaneous-squamous-cell-carcinoma2026-07-31T12:00:00.000Z2026-07-31T12:00:00Z https://www.onclive.com/view/the-future-of-antibody-drug-conjugates-and-oncogene-directed-therapy-in-nsclc2026-07-31T12:00:00Z2026-07-31T12:00:00Z https://www.onclive.com/view/baseline-and-on-treatment-qol-improvements-track-with-survival-benefits-with-belzutifan-or-everolimus-in-ccrcc2026-07-31T12:00:00Z2026-07-31T12:00:00Z https://www.onclive.com/view/the-ca-lems-underdiagnosis-gap-in-small-cell-lung-cancer-prevalence-attribution-bias-and-the-neurology-referral-problem2026-07-31T12:00:00Z2026-07-31T12:00:00Z https://www.onclive.com/view/european-commission-approves-first-line-dato-dxd-for-immunotherapy-ineligible-metastatic-tnbc2026-07-31T10:15:00Z2026-07-31T10:15:00Z https://www.onclive.com/view/dr-choueiri-on-safety-data-from-the-phase-3-litespark-022-trial-in-ccrcc2026-07-30T21:06:12.341Z2026-07-30T21:06:12.341Z https://www.onclive.com/view/fda-ctgtac-ignyte-data-rp1-nivolumab-advanced-melanoma2026-07-30T20:44:35.638Z2026-07-30T20:44:35.638Z https://www.onclive.com/view/biomarker-driven-shifts-signal-the-next-generation-of-mcrc-therapies-with-tanios-s-bekaii-saab-md2026-07-30T20:30:00Z2026-07-30T20:30:00Z https://www.onclive.com/view/individualizing-frontline-treatment-decisions-in-egfr-mutant-nsclc2026-07-30T19:05:00.000Z2026-07-30T19:05:00Z https://www.onclive.com/view/introduction-to-the-evolving-egfr-mutant-nsclc-treatment-landscape2026-07-30T19:00:00.000Z2026-07-30T19:00:00Z https://www.onclive.com/view/poor-prognostic-factors-and-frontline-treatment-selection2026-07-30T18:45:18.845Z2026-07-30T18:45:18.845Z https://www.onclive.com/view/dr-galsky-on-data-supporting-the-fda-approval-of-perioperative-ev-pembrolizumab-in-mibc2026-07-30T18:37:28.827Z2026-07-30T18:37:28.827Z https://www.onclive.com/view/dr-barot-on-the-fda-approval-of-palbociclib-trastuzumab-pertuzumab-in-her2-breast-cancer2026-07-30T18:00:00Z2026-07-30T18:00:00Z https://www.onclive.com/view/navigating-fixed-durations-regimens-in-cll-and-improving-outcomes-for-high-risk-patients-with-john-n-allan-md2026-07-30T17:35:15.027Z2026-07-30T17:35:15.027Z https://www.onclive.com/view/dana-farber-researchers-identify-cdk8-as-a-potential-therapeutic-target-for-alveolar-rhabdomyosarcoma2026-07-30T16:00:00Z2026-07-30T16:00:00Z https://www.onclive.com/view/fda-grants-priority-review-to-subcutaneous-amivantamab-in-head-and-neck-cancer2026-07-30T15:31:11.642Z2026-07-30T15:31:11.642Z https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-enzomenib-for-acute-lymphoblastic-leukemia2026-07-30T15:08:27.527Z2026-07-30T15:08:27.527Z https://www.onclive.com/view/dr-tolaney-on-questions-regarding-treatment-duration-in-her2-metastatic-breast-cancer2026-07-30T14:30:00Z2026-07-30T14:30:00Z https://www.onclive.com/view/leukocyte-interleukin-injection-displays-os-benefit-in-pd-l1-low-oral-cancer2026-07-30T14:29:10.461Z2026-07-30T14:29:10.461Z https://www.onclive.com/view/lung-cancer-experts-debate-disease-nuances-to-deliver-patient-centered-care2026-07-30T13:00:00Z2026-07-30T13:00:00Z https://www.onclive.com/view/interpreting-the-top-study-and-comparing-flaura2-and-mariposa-data2026-07-30T12:15:00Z2026-07-30T12:15:00Z https://www.onclive.com/view/community-education-and-managing-myelosuppression2026-07-30T12:05:00Z2026-07-30T12:05:00Z https://www.onclive.com/view/shifting-goals-of-therapy-in-aya-all-from-transplant-to-long-term-remission-with-pediatric-inspired-regimens-and-immunotherapy2026-07-30T12:05:00Z2026-07-30T12:05:00Z https://www.onclive.com/view/future-directions-in-gist-and-combination-strategies2026-06-18T12:05:00.000Z2026-07-30T12:00:00Z https://www.onclive.com/view/dosing-strategies-and-supportive-care2026-07-30T12:00:00Z2026-07-30T12:00:00Z https://www.onclive.com/view/tp53-co-mutation-background-and-the-top-study-design-and-results2026-07-30T12:00:00Z2026-07-30T12:00:00Z https://www.onclive.com/view/precision-advances-have-transformed-lung-cancer-care-but-key-barriers-persist2026-07-30T12:00:00Z2026-07-30T12:00:00Z https://www.onclive.com/view/the-case-for-pediatric-inspired-regimens-in-aya-all-real-world-evidence-and-barriers-to-adoption2026-07-30T12:00:00Z2026-07-30T12:00:00Z https://www.onclive.com/view/sequencing-systemic-and-liver-directed-therapy-in-hla-a-02-01-negative-metastatic-uveal-melanoma-with-marlana-m-orloff-md2026-07-29T18:45:00Z2026-07-29T18:45:00Z https://www.onclive.com/view/fda-advisory-committee-to-weigh-rp1-plus-nivolumab-in-anti-pd-1-pretreated-advanced-melanoma2026-07-29T18:43:02.318Z2026-07-29T18:43:02.318Z https://www.onclive.com/view/dr-hashmi-on-the-identification-of-candidates-for-car-t-cell-therapy-in-early-r-r-myeloma2026-07-29T18:08:19.842Z2026-07-29T18:08:19.842Z https://www.onclive.com/view/fda-grants-rmat-fast-track-designations-cema-cel-mrd-first-line-lbcl-consolidation2026-07-29T16:39:19.416Z2026-07-29T16:39:19.416Z https://www.onclive.com/view/novel-car-t-cell-therapy-offers-promising-option-for-hard-to-treat-kidney-cancer2026-07-29T16:00:00Z2026-07-29T16:00:00Z https://www.onclive.com/view/rasolute-302-and-the-future-of-pancreatic-cancer-treatment-paul-oberstein-md-on-the-kras-breakthrough2026-07-29T14:30:00Z2026-07-29T14:30:00Z https://www.onclive.com/view/dr-secord-on-combining-mocertatug-rezetecan-with-dostarlimab-in-endometrial-cancer2026-07-29T14:30:00Z2026-07-29T14:30:00Z https://www.onclive.com/view/targeted-therapy-expands-into-adjuvant-and-neoadjuvant-settings-for-oncogene-driven-early-stage-nsclc2026-07-29T14:07:38.608Z2026-07-29T14:07:38.608Z https://www.onclive.com/view/ctdna-mrd-testing-helps-predict-outcomes-in-nsclc2026-07-29T13:00:00Z2026-07-29T13:00:00Z https://www.onclive.com/view/the-peak-study-global-randomized-open-label-phase-3-study-evaluating-the-efficacy-and-safety-of-bezuclastinib-sunitinib-vs-sunitinib-as-second-line-treatment-after-imatinib-in-advanced-gastrointestinal-stromal-tumors2026-07-29T12:59:09.578Z2026-07-29T12:59:09.578Z https://www.onclive.com/view/looking-ahead-combinations-new-targets-and-the-path-to-long-term-survival2026-07-29T12:05:00Z2026-07-29T12:05:00Z https://www.onclive.com/view/future-directions-and-five-year-outlook2026-07-29T12:05:00Z2026-07-29T12:05:00Z https://www.onclive.com/view/-lu-edotreotide-vs-everolimus-for-gastroenteropancreatic-neuroendocrine-tumors-compete-a-phase-3-randomized-open-label-superiority-trial2026-07-29T12:00:00Z2026-07-29T12:00:00Z https://www.onclive.com/view/universal-hla-testing-making-it-standard-practice-in-every-clinic2026-07-29T12:00:00Z2026-07-29T12:00:00Z https://www.onclive.com/view/treatment-sequencing-algorithms-and-clinical-approaches2026-07-29T12:00:00Z2026-07-29T12:00:00Z https://www.onclive.com/view/oncology-experts-review-key-asco-2026-data-for-daraxonrasib-and-other-novel-therapies-in-gi-cancers2026-07-29T12:00:00Z2026-07-29T12:00:00Z https://www.onclive.com/view/experts-bridge-oncology-and-neurology-to-catch-lems-earlier-in-sclc-with-misty-d-shields-md-phd-triparna-sen-md-phd-ms-and-ditte-primdahl-md2026-07-28T22:35:26.063Z2026-07-28T22:35:26.063Z https://www.onclive.com/view/dr-appleman-on-prior-data-with-sync-t-therapy-sv-102-in-prostate-cancer2026-07-28T22:07:38.107Z2026-07-28T22:07:38.107Z https://www.onclive.com/view/dr-tarantino-on-the-evolution-of-trop2-directed-adcs-in-first-line-tnbc2026-07-28T21:50:14.664Z2026-07-28T21:50:14.664Z https://www.onclive.com/view/fda-approval-insights-orca-t-raises-the-bar-for-allogeneic-transplants-in-hematologic-malignancies-with-everett-meyer-md-phd2026-07-28T21:34:50.177Z2026-07-28T21:34:50.177Z https://www.onclive.com/view/dr-hurvitz-on-updated-pfs-data-from-the-serena-6-trial-in-breast-cancer2026-07-28T21:05:55.394Z2026-07-28T21:05:55.394Z https://www.onclive.com/view/dr-tarantino-on-updated-safety-data-from-destiny-breast05-in-her2-breast-cancer2026-07-28T20:15:00Z2026-07-28T20:15:00Z https://www.onclive.com/view/long-term-data-refine-the-role-of-immunotherapy-across-early-stage-nsclc-settings2026-07-28T18:47:31.245Z2026-07-28T18:47:31.245Z https://www.onclive.com/view/dana-farber-announces-groundbreaking-research-collaboration-to-improve-quality-of-life-for-patients-with-metastatic-inflammatory-breast-cancer2026-07-28T16:10:55.273Z2026-07-28T16:10:55.273Z https://www.onclive.com/view/ris-rez-meets-pfs-end-point-in-phase-3-trial-for-relapsed-osteosarcoma2026-07-28T15:40:18.979Z2026-07-28T15:40:18.979Z https://www.onclive.com/view/comprehensive-molecular-testing-anchors-biomarker-driven-care-in-advanced-nsclc2026-07-28T15:30:00Z2026-07-28T15:30:00Z https://www.onclive.com/view/docetaxel-remains-unbeaten-in-immunotherapy-refractory-nsclc2026-07-28T15:18:08.144Z2026-07-28T15:18:08.144Z https://www.onclive.com/view/cretostimogene-grenadenorepvec-elicits-durable-complete-responses-and-bladder-preservation-in-bcg-unresponsive-nmibc2026-07-28T14:41:12.950Z2026-07-28T14:41:12.950Z https://www.onclive.com/view/future-directions-for-genomic-testing-in-early-stage-breast-cancer2026-07-28T14:39:02.539Z2026-07-28T14:39:02.539Z https://www.onclive.com/view/early-stage-breast-cancer-multidisciplinary-collaboration-in-genomic-testing2026-07-28T14:39:01.005Z2026-07-28T14:39:01.005Z https://www.onclive.com/view/early-stage-breast-cancer-integrating-genomic-and-clinicopathologic-risk-factors2026-07-28T14:38:59.522Z2026-07-28T14:38:59.522Z https://www.onclive.com/view/early-stage-breast-cancer-long-term-validation-of-genomic-testing2026-07-28T14:38:58.131Z2026-07-28T14:38:58.131Z https://www.onclive.com/view/early-stage-breast-cancer-selecting-genomic-assays-in-clinical-practice2026-07-28T14:38:56.657Z2026-07-28T14:38:56.657Z https://www.onclive.com/view/early-stage-breast-cancer-communicating-recurrence-scores2026-07-28T14:38:55.199Z2026-07-28T14:38:55.199Z https://www.onclive.com/view/early-stage-breast-cancer-rxponder-and-node-positive-disease2026-07-28T14:38:53.599Z2026-07-28T14:38:53.599Z https://www.onclive.com/view/early-stage-breast-cancer-tailorx-and-chemotherapy-decision-making2026-07-28T14:38:52.134Z2026-07-28T14:38:52.134Z https://www.onclive.com/view/early-stage-breast-cancer-timing-of-genomic-testing2026-07-28T14:38:50.522Z2026-07-28T14:38:50.522Z https://www.onclive.com/view/early-stage-breast-cancer-guideline-directed-use-of-genomic-testing2026-07-28T14:38:48.895Z2026-07-28T14:38:48.895Z https://www.onclive.com/view/early-stage-breast-cancer-integrating-genomic-testing-into-clinical-workflow2026-07-28T14:00:00Z2026-07-28T14:00:00Z https://www.onclive.com/view/cost-and-access-future-directions-and-closing-pearls2026-07-28T12:10:00Z2026-07-28T12:10:00Z https://www.onclive.com/view/sequencing-strategies-after-frontline-adc-therapy2026-07-28T12:05:00Z2026-07-28T12:05:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-future-oral-serd-selection-and-personalized-treatment-decision-making2026-07-28T12:05:00Z2026-07-28T12:05:00Z https://www.onclive.com/view/academic-versus-community-practice-considerations-and-performance-status-in-es-sclc2026-07-28T12:05:00Z2026-07-28T12:05:00Z https://www.onclive.com/view/car-t-access-barriers-and-cns-prophylaxis-for-treating-dlbcl2026-07-28T12:05:00Z2026-07-28T12:05:00Z https://www.onclive.com/view/weighing-trial-endpoints-pros-and-treatment-logistics-in-mtnbc2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/outpatient-bispecific-administration-and-workflow-in-dlbcl2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/hr-positive-her2-negative-metastatic-breast-cancer-treatment-sequencing-after-adjuvant-endocrine-therapy-and-transitioning-beyond-endocrine-based-approaches2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/induction-backbone-selection-and-platinum-rechallenge-in-es-sclc2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/fda-finalizes-3-guidance-documents-to-broaden-cancer-clinical-trial-eligibility-criteria2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/remaining-unmet-needs-and-emerging-therapies-in-ptcl2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/leptomeningeal-disease-management-in-egfr-mutated-nsclc-systemic-therapy-radiation-and-intrathecal-options2026-07-28T12:00:00Z2026-07-28T12:00:00Z https://www.onclive.com/view/asco-2026-adc-data-clarify-some-strategies-and-raise-further-questions-for-breast-cancer-care-with-paolo-tarantino-md-phd2026-07-28T02:00:00Z2026-07-28T02:00:00Z https://www.onclive.com/view/fda-approval-insights-first-line-sacituzumab-govitecan-plus-pembrolizumab-for-pd-l1-tnbc-with-sara-m-tolaney-md-mph2026-07-28T01:25:00Z2026-07-28T01:25:00Z https://www.onclive.com/view/fda-approval-insights-orally-disintegrating-nilotinib-tablets-for-cml-with-jorge-e-cortes-md-and-elias-jabbour-md2026-07-27T23:00:07.787Z2026-07-27T23:00:07.787Z